MANF

Across TCGA pan-cancer cohorts, MANF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MANF data layer compared with 28 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MANF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MANF expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where MANF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.505	0.866	<.001	39	view →
PDAC	DFS	Median	All	0.910	0.682	<.001	17	view →
LUAD	OS	Median	II,III,IV	0.473	0.800	.008	10	view →
LSCC	DFS	Tertile	II,III,IV	0.627	0.885	.022	8	view →
HNSC	DFS	Quartile	III,IV	1.000	0.378	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MANF–CCRCC (DFS)

Open the CCRCC breakdown →